Joe Victor brings more than 30 years of experience fostering product innovation and building value for customers, shareholders, and employees. Most recently, he was CEO of privately held DVS Sciences, a designer and manufacturer of a transformational bioanalytical platform including high-end mass cytometry instruments and associated consumables. DVS was sold in early 2014 to Fluidigm, Inc., a leading Life Sciences publicly held company.  Prior to DVS, Mr. Victor was CEO of Applied Precision Inc., a manufacturer of high performance microscopy systems for life sciences research and drug development acquired by GE Healthcare in 2011. Before that he drove significant sales growth, new product development and overall profitability of the Applied Precision business in the roles of President, Sr. VP Life Sciences, VP R&D / Operations, and VP R&D. Prior to Applied Precision, Mr. Victor held various executive management and technical positions in the high technology, aviation, and energy markets.  Mr. Victor holds an MBA from UCLA and MS and BS degrees in engineering from the University of Washington. Mr. Victor is based in the Seattle area and currently serves on the following company board of directors:  Biodesy, Glencoe Software, Precision Nanosystems, Purigen, and RareCyte.  Mr Victor also serves as an advisory board member to the Harvard Program in Therapeutic Science and the UC Davis Ecosystem for Biophotonics Innovation.


Josh is the Founder of Biodesy and the inventor of the Second Harmonic Generation (SHG) technique for studying biological molecules. Prior to securing Series A financing, Josh successfully raised angel financing, was awarded a number of NSF and NIH grants, and obtained key scientific breakthroughs that galvanized the scientific and venture capital communities.  Josh was a postdoctoral fellow in the Dept. of Chemistry at Columbia University and the Dept. of Physics at Utrecht University in the Netherlands, as well as a guest researcher at the Cavendish Laboratory at the University of Cambridge, UK. His expertise and interests are in the areas of Biophysics and Physical Chemistry. At Biodesy he leads a team focused on creating novel techniques with SHG and applying them to major problems in drug discovery and structural biology, including challenging protein targets such as Ras, allosteric modulators, protein-protein and protein-DNA complexes and interactions, and conformational landscapes. Josh received his PhD from Stanford University where he studied the reaction center protein, the marvelous engine at the heart of photosynthesis which converts light into chemical energy.


Ariel G. Notcovich is an accomplished life science executive, with a wide experience in all aspects and stages of product development for life science markets, having worked in startup as well as in corporate environments. Ariel founded ProteOptics during his PhD in Physics at the Technion-Israel Institute of Technology and served as its CTO and CEO. The company developed a multichannel Surface Plasmon Resonance imaging system for the label-free analysis of molecular interactions. ProteOptics was acquired by Bio-Rad Laboratories. Ariel successfully managed the integration, establishing his team as the innovation center for Bio-Rad Life Sciences Group. As a visionary and entrepreneurial leader of Bio-Rad R&D, he created the Protein Technologies R&D group to develop innovative products for life sciences markets. Products developed in Ariel’s group included systems, instrumentation, software, consumables and reagents for imaging, chromatography, gel electrophoresis and blotting, protein interactions and other product lines.


Gayle is responsible for finance and general business activities at Biodesy. Her career has been focused in early stage life science companies. Prior to joining Biodesy, she was VP of Finance at Isostent, CFO at Radiant Medical, and sole proprietor of her own consulting practice, working with numerous life science client companies and helping raise more than $100M in venture funding.  Gayle has led the finance, accounting, human resources, facilities, information technology (IT), and manufacturing engineering functions.  She received her Master’s Degree in Industrial Administration (MSIA) from the Tepper School at Carnegie Mellon University in Pittsburgh, Pennsylvania and her BA in Economics, magna cum laude, from the University of Washington in Seattle, Washington.


Lou leads all engineering activities at Biodesy. He has extensive experience in imaging systems, optical detection, and microfluidics for life science applications, and has developed numerous successful products for the medical diagnostic and bioanalytical research markets. As a consultant, he has designed FDA-cleared products for digital pathology and point-of-care diagnostic testing. He has also held senior engineering management roles in several companies, such as On-Q-ity (formerly CELLective DX), Nanoplex Technologies, and SurroMed, where he has managed teams developing microfluidic devices and instrumentation for analyzing circulating tumor cells in blood samples, automated manufacturing of microparticles and nanoparticles for multiplexed immunoassays, and automated laser-scanning cytometry systems for biomarker discovery and clinical diagnostics. The author or co-author of federal grants totaling $13 million, he holds 15 U.S. patents covering optical instrumentation, nanoparticle manufacturing techniques, and electronic circuitry for communications systems. He received his B.S. and M.S. in Electrical Engineering from Stanford University.


Neil is responsible for worldwide sales, marketing and customer support. He has over 20 years of commercial experience with various life sciences companies including Affymetrix, Millipore and Applied Biosystems. Most recently, Neil was Vice President Commercial Operations at Fluidigm. Prior to joining Fluidigm Neil was Vice President of Sales and Marketing for DVS Sciences, a start-up venture that was acquired by Fluidigm in February of 2014. At DVS, Neil led the commercial strategy and organization that drove significant sales growth and profitability. Before that, Neil held various management and technical roles in the life science market.